MDMA for PTSD pools to g = -0.71; psilocybin for alcohol use disorder to around SMD 0.5.
The MDMA living review covers 6 RCTs and 286 participants, all MAPS-sponsored, with response risk ratio 1.35 and remission 2.25. The alcohol meta-analysis found 6 trials and only 202 participants total, of which 3 were randomized.
